日本語フィールド
著者：Kakiuchi T, Ohtsuka Y, Sato T, Nakayama A, Jinnouchi K, Oka M and Matsuo M題名：Association between Crohn’s Disease and AarF domain-containing kinase 4 glomerulopathy発表情報：Clin J Gastroenterol. 巻: 12 号: 3 ページ: 263-268キーワード：概要：Coenzyme Q10 deficiency causing gastrointestinal symptoms has not been reported. At least 15 genes are involved in CoQ10 biosynthesis, and one of the genes is AarF domain-containing kinase 4 (ADCK4). This case report first showed a patient who presented with Crohn's disease (CD) combined with ADCK4 glomerulopathy (ADCK4-GN). After approximately 2 years of infliximab treatment for CD, this patient has remained in clinical remission with no adverse effects. Moreover, two important findings were obtained: first, individuals with ADCK4-GN may present with complications, such as CD, which is a gastrointestinal disease, and infliximab may be effective for CD associated with ADCK4-GN. Second, infliximab may also be effective and safe for individuals with CD who are undergoing peritoneal dialysis. Thus, the results of the present study may be used in managing patients with such condition, and as a result, better clinical outcomes will be obtained.抄録：英語フィールド
Author：Kakiuchi T, Ohtsuka Y, Sato T, Nakayama A, Jinnouchi K, Oka M and Matsuo MTitle：Association between Crohn’s Disease and AarF domain-containing kinase 4 glomerulopathyAnnouncement information:Clin J Gastroenterol. Vol: 12 Issue: 3 Page: 263-268An abstract：Coenzyme Q10 deficiency causing gastrointestinal symptoms has not been reported. At least 15 genes are involved in CoQ10 biosynthesis, and one of the genes is AarF domain-containing kinase 4 (ADCK4). This case report first showed a patient who presented with Crohn's disease (CD) combined with ADCK4 glomerulopathy (ADCK4-GN). After approximately 2 years of infliximab treatment for CD, this patient has remained in clinical remission with no adverse effects. Moreover, two important findings were obtained: first, individuals with ADCK4-GN may present with complications, such as CD, which is a gastrointestinal disease, and infliximab may be effective for CD associated with ADCK4-GN. Second, infliximab may also be effective and safe for individuals with CD who are undergoing peritoneal dialysis. Thus, the results of the present study may be used in managing patients with such condition, and as a result, better clinical outcomes will be obtained.